R&D News | pharmaphorum

News

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.

News

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

News

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.

News

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Recently hired employees of the FDA and CDC look set to be the latest workers affected by sweeping job cuts implemented by the Trump administration.